Wiskott–Aldrich syndrome protein
Viliuisk encephalomyelitis is a rare neurological disorder that is primarily found in the Yakut people of Siberia. It is characterized by a range of symptoms including fever, headache, vomiting, psychiatric symptoms, seizures, and paralysis. The disease is progressive and often leads to death.
Epidemiology[edit]
Viliuisk encephalomyelitis is endemic to the Yakut people of Siberia. The disease was first described in the 19th century and has been studied extensively since the 1950s. The exact prevalence of the disease is unknown, but it is believed to affect less than 1 in 1,000,000 people worldwide.
Symptoms[edit]
The symptoms of Viliuisk encephalomyelitis vary widely and can include fever, headache, vomiting, psychiatric symptoms, seizures, and paralysis. The disease is progressive, with symptoms worsening over time. In the later stages of the disease, patients may experience severe neurological impairment and death.
Causes[edit]
The cause of Viliuisk encephalomyelitis is unknown. Some researchers believe that the disease may be caused by a virus, while others suggest that it may be due to a genetic predisposition. Further research is needed to determine the exact cause of the disease.
Diagnosis[edit]
Diagnosis of Viliuisk encephalomyelitis is based on the presence of characteristic symptoms, a history of exposure to the Yakut region of Siberia, and the exclusion of other neurological disorders. Diagnostic tests may include blood tests, lumbar puncture, and brain imaging studies.
Treatment[edit]
There is currently no cure for Viliuisk encephalomyelitis. Treatment is supportive and may include pain management, physical therapy, and psychiatric care. In some cases, antiviral medications may be used in an attempt to slow the progression of the disease.
Prognosis[edit]
The prognosis for individuals with Viliuisk encephalomyelitis is poor. The disease is progressive and often leads to severe neurological impairment and death.
See also[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
- Budget GLP-1 shots
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian


